| Study (first author, year of study) | Study patients and main groups | Interventions | Outcomes, results and relationships |
---|---|---|---|---|
1 | Afshar et al., 2012 | Patients with refractory OCD(n = 38) 1- control group (n = 24) 2- experimental group (n = 24) | 1- Control group: placebo, identical pills 2- Experimental group: initial dosage of 600 mg/d of NAC, which doubled weekly to a maximum dose of 2400 mg/d • Serotonin reuptake inhibitor treatment continued throughout the study with the same dose as the preintervention phase • 12 wks follow up | ➢ Y-BOCS: Mean difference 95%CI; − 5.14 [− 6.87, − 3.41] ➢ Adverse effects: no unusual or serious adverse event was observed. The adverse events reported during trial were only gastrointestinal. Eight patients in the NAC group reported nausea/vomiting of mild to moderate intensity compared with 2 patients in the placebo group. Mild diarrhea was reported by 4 patients in the NAC group but none of the patients in the placebo group |
2 | Arabzadeh et al., 2017 | Those with a diagnosis of moderate to severe OCD defined by a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of ≥ 21 (Goodman, Price, Rasmussen, et al., 1989) were included(n = 50) 1- control group (n = 25) 2- experimental group (n = 25) Hepatectomy and radio-chemotherapy were front-line therapies | 1- Control group: Fluvoxamine (200 mg) + placebo 2- Experimental group: Fluvoxamine (200 mg daily) + L-carnosine 500 mg twice per day • Follow up after 10 wks | ➢ Y-BOCS: Mean difference 95%CI; − 3.00 [− 4.70, − 1.30] P value:0.01 ➢ Adverse effects: Headache 6 Dry mouth 6 Nausea 3 Constipation 6 Sweating Frequency of side effects was not different between the two groups. |
3 | Costa et al., 2017 | Patients with OCD (n = 40) 1- control group (n = 22) 2- experimental group (n = 18) | 1- Control group: SRI + Placebo 2- Experimental group: SRI + N-Acetyl Cysteine • 16 wks follow up • During the first week, patients started the trial with either NAC 1200 mg (one 600-mg capsule twice a day) or an equivalent number of placebo capsules. In the second week, the dosage was increased to 4 capsules per day (NAC 2400 mg [2 capsules twice a day] or an equivalent number of placebo capsules). Finally, on the third week, the target dose of 5 capsules per day was reached (NAC 3000 mg [2 capsules in the morning and 3 in the evening] or an equivalent number of placebo capsules) and sustained for the remainder of the study. | ➢ Overall survival in 8 years* (HR; 95%CI; P value): 0.69 (0.41–1.15); P = 0.1545 ➢ Recurrence-free survival in 5 years* (HR; 95%CI; P value): 0.31 (0.09–1.07); P = 0.0639 ➢ Toxicity grade 3–4: none was reported |
4 | Emamzadehfard et al. 2016 | Patients with OCD (n = 54) 1- control group (n = 27) 2- experimental group (n = 27) according to the DSMIV-TR and a Yale–Brown Obsessive Compulsive Scale (Y-BOCS) score of ≥21 | 1. Control group: fluvoxamine 200 mg/day + placebo 2. Experimental group: fluvoxamine 200 mg/day + riluzole 50 mg BD 10 wks follow up | ➢ Y-BOCS: Mean difference 95%CI; − 3.56 [− 6.89, − 0.23] p value:0.04 Adverse effects: Experimental group: Drowsiness, 6 (24%) Constipation, 5 (20%) 5 (20%) Dizziness, 4 (16%)Abdominal pain, n (%) 5 (20%) 4(16%) Increased appetite, n (%) 4 (16%) 5 (20%) Decreased appetite, n (%) 3 (12%) 4 (16%) Nausea, n (%) 6 (24%) 5 (20%) Headache, n (%) 4 (16%) 4 (16%) Dry mouth, n (%) 3 (12%) 3 (12%) Cough, 4 (16%) Diarrhea, 6 (24%) 4 (16%) Increase in liver-function tests (4%) 0 |
5 | Esalatmanesh et al., 2016 | Patients with OCD Y-BOCS > 21 (n = 132) 1- control group (n = 66) 2- experimental group (n = 66) • Almost half of the patients had hepatitis B • Hepatectomy or TACE were frontline therapies | 1- Control group: Fluvoxamine 200 mg/day + placebo (identical, same shaped capsule) 2- Experimental group: Fluvoxamine 200 mg/day + Minocycline 100 mg twice daily 10 wks follow up | ➢ Y-BOCS: Mean difference 95%CI; −3.21 [− 0.84– − 5.58] p value:0.008 ➢ Adverse effects: No difference between to gropus |
6 | Farnia et al., 2018 | Patients with OCD (n = 99) 1- control group (n = 33) 2- experimental group 1 (n = 33) 3- experimental group 2 (n = 33) | 1. Control group: Fluoxetine 40 mg/day + placebo (identical pills) 2. Experimental group 1: Fluoxetine 40 mg/day + gabapentin 300 mg/day 3. Experimental group 2: Fluoxetine 40 mg/day + memantine 10 mg/day • From baseline to the end of the fourth week, daily dosage of fluoxetine was 20 mg; from the beginning of the fifth week to the end of the eighth week, daily dosage of fluoxetine was 40 mg. • From baseline to the end of the fourth week, daily dosage of gabapentin was 100 mg; fromthe beginning ofthe fifthweek to theend of the eighth week, daily dosage of gabapentin was 300 mg • memantine was given daily at 5 mg in the morning/evening for the four first weeks of the study, and then increased to 10 mg daily for weeks five to eight. Likewise, placebos were given daily in the morning/evening | ➢ memantine vs. placebo: Mean difference 95% CI: - 1.12 [− 0.916, −  3.1622] P-value:0.2 ➢ Gabapentin vs. placebo Mean difference 95% CI: - 2.550[− 0.7895, −  4.3105] P-value:0.0061 ➢ Adverse effects: More rash was seen in memantine group than control group Sleepiness was reported in gabapentin group |
7 | Ghaleiha et al., 2013 | Patients with OCD (n = 42) • control group (n = 21) • experimental group (n = 21) | 1- Control group: fluvoxamine 200 mg/day + placebo (with the same shape and taste as memantine) 2- Experimental group: fluvoxamine 200 mg/day + memantine 20 mg/day • All patients received fluvoxamine100mg/ day for the first four weeks of the trial followed by 200 mg/day for the rest of the study • 8 wks follow up | • Y-BOCS: has not reported the mean of score after the trial. Just reports remission rate • Adverse effects in control group: Drowsiness (26%) Headache (21%) Constipation (31%) Dizziness (21%) Fatigue (16%) Nausea (21%) Decreased appetite (26%) Itching (10%) Nervousness (21%) Rash (5%) in experimental group: Drowsiness (21%) Headache (16%) Constipation (31%) Dizziness 3 (16%) Fatigue (16%) Nausea (26%) Decreased appetite (21%) Itching (16%)Nervousness (21%) Rash (10%) |
8 | Greenberg et al., 2009 | Patients with OCD (n = 24) • control group (n = 12) • experimental group (n = 12) | 1. Control group: placebo fluid (dextrose, fructose, fine granular citric acid, orange flavoring and ProSweetTM flavor enhancer) 2. Experimental group: glycine powder 30 g dissolved in water or juice, twice daily • The experimental intervention was adjunctive to participants’ continuing psychotropic and psychotherapeutic regimens, which were managed by their treatment providers in the community. • 12 wks follow up | ➢ Y-BOCS: Mean difference 95%CI; −5.30 [− 11.56, 0.96];p value: 0.1650 ➢ Adverse effects: constipation 1; nausea or disagreeable taste 8 out of 16 dropped patients |
9 | Haghighi et al., 2013 | Patients with OCD (n = 40) • control group (n = 20) • experimental group (n = 20) | 1- Control group: placebo (identical pill) 2- Experimental group: memantine (5–10 mg/day) • All patients use medication 1 week prior to the beginning of the study (and continued throughout the study) of an SSRI (e.g., escitalopram, 10 mg/day; citalopram, 30–50 mg/day) or clomipramine (100–175 mg/day) at therapeutic dosages for at least 12 consecutive weeks • 12 wks follow up | ➢ Y-BOCS: Mean difference 95%CI; −3.21 [− 0.84– − 5.58] p value:0.008 ➢ Adverse effects: light-headedness and vertigo 5% (similar to placebo group) |
10 | Modarresi et al., 2018 | Patients with OCD (n = 32) • control group (n = 16) • experimental group (n = 16) | 1- Control group: placebo (identical pills) 2- Experimental group: memantine 10 mg/day • Patients continue their SRI therapy during the study • 12 wks follow up | ➢ Y-BOCS: Mean difference 95%CI; −13.53 [− 15.59, − 11.47] p value< 0.001 ➢ Adverse effects: Headache 13.3%Constipation6.6% Nausea 6.6% Dizziness 13.3% Decreased appetite 6.6% |
11 | Mowla et al., 2019 | Patients with OCD (n = 56) • control group (n = 28) • experimental group (n = 28) • the patients in this study had failed to respond to at least 12 weeks of treatment with an adequate and stable dose of sertraline, as reflected by a baseline Yale–Brown Obsessive Compulsive Scale (YBOCS) of 18 or greater before enrollment in our trial | 1- Control group:sertraline + placebo (identical pills 2- Experimental group: Sertraline + pregabalin (75 mg/day initialy, increase 75 mg weekly • The sertraline dosage had been tittered up until patient’s intolerance. • No pregabalin dose escalation was administered in the case of patient’s intolerance or clinical response. | ➢ Y-BOCS: Mean difference 95%CI; −8.82 [− 11.17, − 6.47] p value< 0.001 ➢ Adverse effects: Dizziness 4%, drowsiness 18%, headache 4% |
12 | Naderi et al., 2019 | Patients with OCD (n = 106) • control group (n = 53) • experimental group (n = 53) • The patients were not allowed to have received any psychotropic medications during the last 6 weeks or to have participated in psychotropic sessions • met the DSM-5 diagnostic criteria for moderate to severe OCD and had a Yale–Brown Obsessive Compulsive Scale (Y-BOCS) score of > 21 | 1- Control group: fluvoxamine (100 mg twice a day) + placebo 2- Experimental group: fluvoxamine (100 mg twice a day) + amantadine (100 mg daily) • All patients received 100 mg/day fluvoxamine for 28 days, which was followed by 200 mg/day for the rest of the trial, regardless of their treatment groups | ➢ Y-BOCS: Mean difference 95%CI; − 2.31 [− 4.58, − 0.04] p value:0.047 Adverse effects: Abdominal pain (5.8%) Decreased appetite (3.9%) Increased appetite (3.9%) Insomnia (1.9%) Headache (3.9%) Nervousness (1.9%) Tremor (1.9%) Constipation (3.9%) |
13 | Paydari et al., 2016 | Patients with OCD (n = 46) • control group (n = 23) • experimental group (n = 23) • (DSM-IV TR) criteria of moderate-to-severe OCD and scored ≥21 in Y-BOCS | 1- Control group: fluvoxamine (200 mg daily) + placebo (identical pills) 2- Experimental group: fluvoxamine (200 mg daily) + NAC (2000 mg daily) • The NAC initial dosage was 1000 mg/day (500 mg two times a day) for the first week, followed by 2000 mg/day (1000 mg bid) for the subsequent 9 weeks • 10 wks follow up | ➢ Y-BOCS: Mean difference 95%CI; − 2.04 [− 4.97, − 0.88] p value:0.16 ➢ Adverse effects: Drowsiness, 18% Constipation 23% Dizziness 27% Vomiting27% Nausea27% Headache18% Dry mouth14% Increased blood Pressure14% Diarrhoea18% |
14 | Pittenger et al., 2015 | Patients with OCD (n = 38) 1- control group (n = 18) 2- experimental group (n = 20) • treatment with an SSRI or clomipramine at a stable effective dose for 8 weeks (by patient report) is an item in inclusion criteria | 1- Control group: Placebo 2- Experimental group: riluzole 50 mg bid • all subjects began with a 2-week single-blind placebo lead-in phase, followed by 12 weeks of double-blind riluzole or placebo. In posttrial debriefing, no subjects expressed awareness of this initial placebo lead-in phase. Any subjects experiencing a greater than 25% improvement in the Y-BOCS over this 2-week placebo lead-in phase were excluded from randomization. • 12 wks follow up • Low-dose stable neuroleptic augmentation and benzodiazepine use were permitted • Ongoing psychotherapy of 12 weeks duration was permitted | ➢ Y-BOCS: Mean difference 95%CI: − 4.5[− 6.5074, − 2.4926] p value:0.002 ➢ Adverse effects: Nausea: < 10% in experimental group |
15 | Rodriguez 2013 | Patients with OCD (n = 38) 1. control group (n = 18) 2. experimental group (n = 20) • Patients on average were off all psychotropic medications for 2.9 years | 1. Control group: Placebo (saline infusion) 2. Experimental group: Ketamine infusion(0.5 mg/kg) • Cross-over study • One week duration • Include only the first period of study, because of significant carryover effect | ➢ Y-BOCS: Mean difference 95%CI − 5.46 [− 13.15, 2.22] p value: 0.1868 ➢ Adverse effects: ° During infusion: Dissociation: 93% unusual content of thought:87% elevated mood: 7% ° Post-infusion:dizziness 20% nausea: 13% headache 13% ° All side effects were resolved after 110 min of infusion |
16 | Rutrick et al., 2017 | Patients with OCD (n = 50) 1. control group (n = 24) 2. experimental group (n = 26) • All patients had used SRI for 12wks before baseline and had insufficient response (Y-BOCS score > 16) | 1. Control group: Placebo 2. Experimental group: Magovlurant 200 mg BiD • 19 wks follow up. First 4 wks for dose titration and last 3 wks for taper of mavoglurant • During the study patients remained on their SSRI treatment • Patients who were receiving cognitive behavioral therapy (CBT) as a part of their standard care continued to receive this therapy for the duration of the study. | ➢ Y-BOCS: Mean difference 95%CI 1.80 [−4.30, 7.90] p value: 0.5658 ➢ Adverse effects [placebo(%) vs experimental(%)]: Headache 8 (33.3) 10 (38.5) Insomnia 2 (8.3) 6 (23.1) Dizziness 2 (8.3) 5 (19.2) Nasopharyngitis 4 (16.7) 2 (7.7) Abdominal pain upper 1 (4.2) 2 (7.7) Abnormal dreams 1 (4.2) 2 (7.7) AST increased 1 (4.2) 2 (7.7) Depression 2 (8.3) 1 (3.8) Fatigue 1 (4.2) 2 (7.7) Vertigo 1 (4.2) 2 (7.7) |
17 | Sarris et al., 2015 | Patients with OCD (n = 50) 1. control group (n = 24) 2. experimental group (n = 26) • patients were on either no treatment or a stable treatment regimen for a minimum of four weeks of current treatment and a minimum of 12 weeks if this is their first OCD treatment | 1. Control group: Same shaped cellulose capsule 2. Experimental group: NAC 3000 mg/day • 16 wks follow up • NAC was titrated, 1000 mg/day in week 1, 2000 mg/day in week 2 | ➢ Y-BOCS: Mean difference 95%CI; − 2.04 -0.59 [− 6.31, 5.13] p value: 0.8425 ➢ Adverse effects: heartburn 20% |